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Neisseria meningitidis is an important cause of invasive
bacterial infection in children worldwide, and is a rare
example of a bacterium that has evolved to become an
obligate human commensal which commonly colonizes
the oropharyngeal mucosa. Carriage is age-dependent
and appears to be very common in young adults. The
relationships between carriage and invasive disease are
not completely understood [1].
Each year approximately 1.2 million cases of invasive
meningococcal disease (sepsis or meningitis) with
135,000 deaths are estimated to occur worldwide [2].
Epidemiology and serogroup distribution differs geogra-
phically, as the example in Figure 1 shows, with invasive
disease mainly affecting young children, older children
and young adults. In addition to age, another individual
risk factor includes underlying immune deficiencies; the
deficiency of complement components is a known risk fac-
tor for invasive infection. Crowding and concurrent upper
respiratory tract infections might also contribute to the
disease.
In early 2013, a new vaccine developed specifically to
prevent disease caused by group B meningococci (MenB)
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Figure 1 Variations in the proportion of strains of serogroup B, C and Y circulating in Italy
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was licensed in Europe (4CMenB, Bexsero©, Novartis Vac-
cines, Italy). This vaccine is protein-based and, therefore,
compared to meningococcal conjugate vaccines, has a dif-
ferent mechanism of action, along with different safety,
reactogenicity and immunogenicity profiles in the various
age groups.
The vaccine, developed by reverse vaccinology, contains
three surface-exposed recombinant proteins (fHbp, NadA,
and NHBA) and outer membrane vesicles derived from
the NZ98/254 strain and has the potential to reduce
mortality and morbidity associated with serogroup B
meningococci infections, but uncertainty remains about
the breadth of protection the vaccine might induce against
the diverse serogroup B meningococci strains that
cause disease: Meningococcal Antigen Typing System
predicted that 78% of all MenB strains would be killed by
postvaccination [3].
In Italy (updated April 2014) the Basilicata Region [4]
recommend Bexsero for the routine vaccination of infants
and will have an active call to parents that includes provid-
ing the vaccine free of charge. The Board of Calendario
per la Vita, comprising of the country’s foremost scientific
societies, has recommended Bexsero for all infants with
three doses in the first year of life and one dose at 13
months of age [5].
For parents and clinicians, the predicted benefits of
4-component meningococcal group B vaccine (4CMenB)
outweigh existing uncertainties about the potential
impact of the MenB vaccine against invasive disease, but
future introduction of the vaccine must be followed by
rigorous post-implementation surveillance to assess its
value to health systems.
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